The PDE4 inhibitor tanimilast shows distinct immunomodulatory properties associated with a type 2 endotype and CD141 upregulation
2022 · Journal of Translational Medicine · 5 citations
https://doi.org/10.1186/s12967-022-03402-x
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
10
Papers
207
Citations
6
h-index
5
i10-index
Mauro Passari is an academic researcher from University of Brescia. The author has contributed to research in topics: Immune Response and Inflammation & SARS-CoV-2 and COVID-19 Research & Cell Adhesion Molecules Research. The author has an h-index of 6, co-authored 9 publications.
ORCID: 0000-0002-0502-7865https://doi.org/10.1186/s12967-022-03402-x
https://doi.org/10.1038/s41598-024-77694-y
Click to start Chat